Vor Biopharma Reports Third Quarter 2026 Financial Results
Vor Biopharma (VOR) has released its financial results for the third quarter of 2026, reporting a net loss of $86.7 million. This represents a significant improvement in bottom-line performance compared to the $812.7 million net loss recorded during the same period in the previous year. The company maintains a strong liquidity position with $481.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Management projects that these existing funds are sufficient to finance the company's operations into early 2029.
Tickers: $VOR
Topics: cash runway net loss quarterly earnings